Inventor · disambiguated record
Ling Wang
Also filed as: WANG LING · WANG LING-MEI
35 granted patents·21 pending applications·377 citations·filing 1995–2024
97Inventor score
Files withPURDUE PHARMA LP8NOVAGEN HOLDING CORP7IND TECH RES INST5NANOGEN INC4SUZHOU ALPHAMAB CO LTD3
Top patents by PatentIndex Score
56 records- 0195US6379897B1Methods for gene expression monitoring on electronic microarraysNANOGEN INC·Filed 2000·Granted Apr 30, 2002·171 cites·42 claims
- 0294US8809530B1Compositions of protein receptor tyrosine kinase inhibitorsVM PHARMA LLC·Filed 2014·Granted Aug 19, 2014·33 cites·23 claims
- 0391US9388146B2Crystalline forms of tyrosine kinase inhibitors and their saltsPURDUE PHARMA LP·Filed 2015·Granted Jul 12, 2016·8 cites·31 claims
- 0491US7625555B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2007·Granted Dec 1, 2009·13 cites·34 claims
- 0589US8999992B2Crystalline forms of tryosine kinase inhibitors and their saltsVM PHARMA LLC·Filed 2014·Granted Apr 7, 2015·10 cites·21 claims
- 0686US9040508B2Compositions of protein receptor tyrosine kinase inhibitorsWU JAY JIE-QIANG·Filed 2009·Granted May 26, 2015·7 cites·12 claims
- 0784US8425895B2Recombinant human interferon-like proteinsWANG HAITAO·Filed 2007·Granted Apr 23, 2013·4 cites·48 claims
- 0882US10124002B2Crystalline forms of tyrosine kinase inhibitors and their saltsPURDUE PHARMA LP·Filed 2017·Granted Nov 13, 2018·2 cites·20 claims
- 0982US9738659B2Compositions of protein receptor tyrosine kinase inhibitorsPURDUE PHARMA LP·Filed 2015·Granted Aug 22, 2017·3 cites·21 claims
- 1081US9993473B2Crystalline forms of tyrosine kinase inhibitors and their saltsPURDUE PHARMA LP·Filed 2016·Granted Jun 12, 2018·2 cites·31 claims
- 1181US9718794B2Crystalline forms of tyrosine kinase inhibitors and their saltsPURDUE PHARMA LP·Filed 2014·Granted Aug 1, 2017·3 cites·33 claims
- 1280US7868151B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·14 claims
- 1379US9234022B2Recombinant human interferon-like proteins and method of treatment using themNOVAGEN HOLDING CORP·Filed 2013·Granted Jan 12, 2016·2 cites·42 claims
- 1479US6492122B2Quantitative analysis methods on active electronic microarraysNANOGEN INC·Filed 2001·Granted Dec 10, 2002·27 cites·14 claims
- 1578US7867482B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·30 claims
- 1676US11377497B2PD-L1 binding polypeptide or compositeSUZHOU ALPHAMAB CO LTD·Filed 2018·Granted Jul 5, 2022·2 cites·11 claims
- 1773US11739382B2Compositions and methods for amplification and detection of hepatitis B virus RNA, including HBV RNA transcribed from cccDNAROCHE MOLECULAR SYSTEMS INC·Filed 2020·Granted Aug 29, 2023·1 cites·78 claims
- 1873US5925529AMethod for discovery of peptide agonistsUNIV CALIFORNIA·Filed 1995·Granted Jul 20, 1999·48 cites·15 claims
- 1973US2020369741A1Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2019·Application pending·0 cites
- 2069US10538565B2Method of treating diseases with recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2018·Granted Jan 21, 2020·0 cites·14 claims
- 2168US8476458B2Methods and compositions for modulating P300/CBP activityMARMORSTEIN RONEN·Filed 2008·Granted Jul 2, 2013·2 cites·2 claims
- 2267US2024366763A1Claudin 18.2 t cell-antigen couplers and uses thereofTRIUMVIRA IMMUNOLOGICS USA INC·Filed 2024·Application pending·0 cites
- 2364US12016923B2Claudin 18.2 T cell-antigen couplers and uses thereofTRIUMVIRA IMMUNOLOGICS USA INC·Filed 2022·Granted Jun 25, 2024·0 cites·18 claims
- 2464US6468742B2Methods for determination of single nucleic acid polymorphisms using bioelectronic microchipNANOGEN INC·Filed 1999·Granted Oct 22, 2002·32 cites·125 claims
- 2563US2025051731A1Compositions and methods for establishment of bovine-induced pluripotent stem cellsUNIV CONNECTICUT·Filed 2022·Application pending·0 cites
- 2662US9982028B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2016·Granted May 29, 2018·0 cites·27 claims
- 2761US10421763B2Compositions of protein receptor tyrosine kinase inhibitorsPURDUE PHARMA LP·Filed 2017·Granted Sep 24, 2019·0 cites·15 claims
- 2861US8758756B2Anti-human epidermal growth factor receptor antibody and uses thereofWANG HSIANG-CHING·Filed 2012·Granted Jun 24, 2014·1 cites·15 claims
- 2960US11629180B2Bifunctional angiogenesis inhibitor and use thereofREMEGEN CO LTD·Filed 2019·Granted Apr 18, 2023·0 cites·21 claims
- 3060US11040056B2Benzimidazoles that enhance the activity of oligonucleotidesUNIV NORTH CAROLINA CHAPEL HILL·Filed 2019·Granted Jun 22, 2021·0 cites·23 claims
- 3158US12098176B2Keratin BD-4, preparation method, and pharmaceutical composition and use thereofINST MATERIA MEDICA CAMS·Filed 2020·Granted Sep 24, 2024·0 cites·6 claims
- 3254US2021322456A1Benzimidazoles that enhance the activity of oligonucleotidesUNIV NORTH CAROLINA CHAPEL HILL·Filed 2021·Application pending·0 cites
- 3353US2022275465A1COMPOSITIONS AND METHODS FOR AMPLIFICATION AND DETECTION OF HEPATITIS B VIRUS RNA, INCLUDING HBV RNA TRANSCRIBED FROM cccDNAROCHE MOLECULAR SYSTEMS INC·Filed 2022·Application pending·0 cites
- 3452US2018142214A1In vitro method for screening testing compound to evaluate its potential as liver drugIND TECH RES INST·Filed 2018·Application pending·0 cites
- 3552US2015159141A1Isolated human liver tumor cell line and method of agent screeningIND TECH RES INST·Filed 2014·Application pending·0 cites
- 3652US2024016841A1Cells comprising t cell-antigen couplers and uses thereofTRIUMVIRA IMMUNOLOGICS USA INC·Filed 2021·Application pending·0 cites
- 3752US2023061378A1Pertussis toxin binding proteinSUZHOU ALPHAMAB CO LTD·Filed 2020·Application pending·0 cites
- 3851US2023174660A1Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancerIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3951US2024247076A1Coagulation factor xi (fxi) binding proteinSUZHOU ALPHAMAB CO LTD·Filed 2021·Application pending·0 cites
- 4051US2015160195A1Human liver tumor cell line and method of agent screeningIND TECH RES INST·Filed 2014·Application pending·0 cites
- 4150US9138439B2Methods and compositions for modulating P300/CBP activityWISTAR INST·Filed 2013·Granted Sep 22, 2015·0 cites·2 claims
- 4248US2024124556A1Keratin bd-3, preparation method therefor and pharmaceutical composition and use thereofINST MATERIA MEDICA CAMS·Filed 2020·Application pending·0 cites
- 4347US11674133B2Methods and compositions for extracting nucleic acids using ferric oxide particlesBECTON DICKINSON CO·Filed 2018·Granted Jun 13, 2023·0 cites·10 claims
- 4447US2018143181A1In vitro method for screening testing compound to evaluate its potential as liver drugIND TECH RES INST·Filed 2018·Application pending·0 cites
- 4546US2023287068A1Keratin bd-6, preparation method therefor and pharmaceutical composition and use thereofINSTITUTE OF MAT MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES·Filed 2020·Application pending·0 cites
- 4646US2022411513A1Anti-pd-l1 antigen binding protein and application thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
- 4746US2002119470A1Magnetic bead-based array for genetic detectionFiled 2001·Application pending·0 cites
- 4845US7714146B2Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agentsIND TECH RES INST·Filed 2007·Granted May 11, 2010·0 cites·8 claims
- 4944US7582421B2Methods for determination of single nucleic acid polymorphisms using a bioelectronic microchipNANOGEN INC·Filed 2002·Granted Sep 1, 2009·2 cites·8 claims
- 5043US2011224300A1USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIAINST OF MATARIA MEDICA CHINESE ACADEMY OF ME·Filed 2008·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ling Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →